Evaluación de la dosis efectiva de inhibidores de bomba de protones en pacientes con enfermedad por reflujo gastroesofágico erosivo en el Centro de Gastroenterología González de enero del 2016 a diciembre del 2023

Abstract

Background: Gastroesophageal reflux disease is a condition that occurs when the stomach contents flow towards the esophagus causing irritation. To alleviate this, proton pump inhibitors are used that mitigate the amount of gastric acid produced by the glands in the lining of the stomach. Objective: to evaluate the effective dose of proton pump inhibitor in patients with erosive esophageal reflux disease at the González Gastroenterology Center from 2016 to 2023. Methodology: descriptive, retrospective study with 176 patients from the González Gastroenterology Center from 2016 to 2023. Information collected from medical records was processed in SPSS27. Frequencies and percentages were used to show the results of the variables. Results: Patients aged 40 years or older (84.7%), without distinction of sex, urban residence (86.4%) and mestizos (97.2%) were predominant. The diagnosis was mainly made by endoscopy (81.8%). The treatments used were mainly lansoprazole and dexlansoprazole, in doses of 40 or 60 mg respectively and with varying frequencies. 99.4% reported being asymptomatic after therapy and a single case presented diarrhea as an adverse effect. Conclusions: The minimum effective dose was 40 mg in 48.9% of patients. To control the disease, 41.5% required one dose a day, while 23.9% needed one dose on Mondays, Wednesdays and Fridays. There was a positive and statistically significant relationship between the daily dose increase and the severity of erosive esophagitis in cases with endoscopic diagnosis.